ACAD

ACADIA PHARMACEUTICALS INC

Healthcare | Mid Cap

$0.24

EPS Forecast

$334.1

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Acadia Q2 2026: DayBUE Uptake, NUPLAZID Strength, and a Raised Revenue Forecast

Lede: two franchises, one narrative

ACAD (Nasdaq: ACAD) lays out a quarter that looks less like a one-off pop and more like a march toward a bigger 2026. The company reports GAAP net sales of $125 million for DAYBUE in the second quarter, up about 30% from a year earlier, with DAYBUE fueling growth on the neurology and neurodevelopment side. NUPLAZID contributions show GAAP net sales of $183 million, up roughly 10% year over year on a non-GAAP adjusted basis. In other words, two engines humming, and a farm team ready to sprint if the Phase 2 readouts land as hoped.

Financial snapshot and guidance in plain English

  • Revenue mix: DAYBUE contributed materially to the quarterly uplift; NUPLAZID continued to be a dependable contributor.
  • EPS note: The release does not provide EPS figures or EPS consensus. No earnings surprise is disclosed at the GAAP net sales line, but the focus is clearly on topline growth and pipeline milestones rather than a quarterly earnings beat in the traditional sense.
  • Revenue forecast: Acadia raised its full-year 2026 total revenue guidance to a range of $1.24 billion to $1.30 billion. The uplift reflects higher DAYBUE revenue expectations ($480 million to $510 million) and reaffirmed NUPLAZID guidance ($760 million to $790 million).
  • Regulatory and pipeline milestones: topline results from the Phase 2 remlifanserin study in Alzheimer's disease psychosis are expected in September to October 2026. FDA Fast Track designation was granted for remlifanserin as a treatment for hallucinations and delusions in Alzheimer's disease psychosis, signaling potential for expedited review if the data cooperate.
  • EU update: the Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion recommending DAYBUtrofinetide (DAYBU) for Rett syndrome; if approved by the European Commission, it would become the first approved Rett syndrome treatment in the EU.

Product and pipeline updates

In a busy portfolio moment, Acadia notes completion of enrollment in the Phase 2 portion of the RADIANT program evaluating remlifanserin in Alzheimer's disease psychosis, with Phase 3 screening and enrollment now underway. The company frames these developments as progress toward a potential transformational opportunity if topline Phase 2 results come in during September to October 2026.

On the Rett syndrome front, the EU positive opinion for DAYBUtrofinetide (DAYBU) could unlock a meaningful regional expansion if the European Commission grants authorization. That would be a meaningful milestone for a company built on two wholly different disease targets and regulatory paths.

Management commentary and tone

In the press release, CEO Catherine Owen Adams casts Q2 as a validation of the company’s dual-path strategy—continue to leverage DAYBUE for developmental and pediatric neurology indications while expanding the NUPLAZID franchise in the core adult market. The tone nods to discipline in forecasting and a readiness to lean into regulatory milestones as tailwinds rather than mere marketing chatter.

What this might portend for Acadia and peers

The combination of accelerating DAYBUE momentum, a raised revenue forecast, and regulatory chatter around Rett syndrome sets a constructive tone for the sector. For sector peers, the signal is twofold: if DAYBUE’s EU pathway advances and REM lifters begin to show clear topline signals, investors may reprice Rett syndrome opportunities higher, even as competition remains patient and regulatory timelines remain non-linear.

The FDA Fast Track designation for remlifanserin skews attention toward expedited pathways for compounds addressing high unmet medical needs. If topline Phase 2 results in Alzheimer’s disease psychosis align with expectations, the company might earn credibility on its Alzheimer’s program that could influence broader market sentiment toward similar anti-psychosis efforts in neurodegenerative diseases.

In the nearer term, the absence of an explicit EPS figure in the release means the stock’s immediate reaction will hinge on the trajectory of revenue, progress toward Phase 2/Phase 3 milestones, and regulatory signals rather than a clean quarterly earnings surprise. In Matt Levine’s world, that translates into: the narrative is a bet on the pipeline, not a single quarterly stat.

Forthright notes for readers

Ticker: ACAD. EPS: not disclosed in this release; no EPS consensus is stated. Revenue forecast: raised for 2026 to $1.24–$1.30 billion. Earnings surprises: not reported in the quarter’s disclosure. R&D milestones: Phase 2 remlifanserin topline in Sep–Oct 2026; FDA Fast Track for remlifanserin; EMA positive opinion for DAYBUtrofinetide in Rett syndrome. These are the vectors investors will watch as the year unfolds.

The Acadia story remains a study in dual engines: a steady day-to-day generator in NUPLAZID and a growth engine in DAYBUE, all while pipeline dynamics and regulatory moves create the kind of crosscurrents that keep analysts busy—and investors hopeful that 2026 ends with a stronger cadence than it began.